

Press release

Zug, 4 September 2009

HBM BioVentures Ordinary Shareholders' Meeting All Board of Directors' proposals approved with clear majority

At today's ordinary shareholders' meeting of HBM BioVentures Ltd all of the motions put forward by the Board of Directors were approved. Mr Robert Ingram and Dr. Rudolf Lanz were re-elected to the Board, while Mr Hans Peter Hasler was appointed as a new member.

HBM Bioventure's shareholders approved the re-election of the two existing directors, Robert Ingram and Dr. Rudolf Lanz, for a term of three years. They also appointed a new Board member, Mr Hans Peter Hasler, who served as Chief Operating Officer of one of the world's biggest biotech companies, Biogen Idec Inc. and Biogen International, until early 2009.

The reduction of the share capital to CHF 642'000'000 by cancelling 562'859 registered shares at a par value of CHF 60 was approved. Once the reduction has been completed, the relevant entry in the Commercial Register will state that 10'700'000 registered shares at a par value of CHF 60 remain outstanding.

The Board of Directors of HBM BioVentures Ltd. decided at today's meeting to launch a new share buy-back programme for up to 20% of the shares on 7 September 2009. The shareholders authorised the new share buy-back programme that extends to a maximum of 20% of outstanding shares. The share buy-back programme initiated in September 2008 is terminated with immediate effect.

For further information, please contact Dr. Andreas Wicki, CEO HBM BioVentures Ltd, tel.: +41 41 768 11 08, andreas.wicki@hbmbioventures.com.

Brief profile of HBM BioVentures Ltd

As a venture capital company, HBM BioVentures is invested globally in some 35 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of many of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on unlisted emerging companies, Two thirds of investment capital is invested in private companies with high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA



position. HBM BioVentures has a broad shareholder base and is listed on the SWX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM BioVentures Ltd
Bundesplatz 1
CH-6300 Zug/ Switzerland
Tel:+41 41 768 11 08
Fax:+41 41 768 11 09
info@hbmbioventures.com
www.hbmbioventures.com